Toon S, Davidson E M, Garstang F M, Batra H, Bowes R J, Rowland M
Pharmacokinetic Department, Medeval Ltd., University of Manchester, UK.
Clin Pharmacol Ther. 1988 Mar;43(3):283-9. doi: 10.1038/clpt.1988.34.
The effects of concomitant administration of cimetidine and ranitidine on the pharmacokinetics and pharmacodynamics of multiple-dose metoprolol were investigated in 12 normal, healthy male volunteers. The pharmacokinetics of metoprolol were assessed in terms of racemic metoprolol and the individual (R)- and (S)-enantiomers with a stereoselective assay. Ranitidine had no effect on the pharmacodynamics or pharmacokinetics of metoprolol. Although not affecting the pharmacodynamics of metoprolol, cimetidine did produce an increase in the bioavailability of metoprolol through inhibition of enzymes responsible for the first-pass elimination of the beta-blocker. The effect was stereoselective, with the major effect being on the less pharmacologically active (R)-enantiomer.
在12名正常、健康的男性志愿者中研究了西咪替丁和雷尼替丁联合给药对多次服用美托洛尔的药代动力学和药效学的影响。采用立体选择性分析法,根据消旋美托洛尔以及单个(R)-和(S)-对映体评估美托洛尔的药代动力学。雷尼替丁对美托洛尔的药效学或药代动力学没有影响。尽管不影响美托洛尔的药效学,但西咪替丁通过抑制负责β受体阻滞剂首过消除的酶,确实使美托洛尔的生物利用度增加。这种作用具有立体选择性,主要作用于药理活性较低的(R)-对映体。